LOS ANGELES — Jonathan M. Spergel, MD, PhD, chief of the allergy section at the Children’s Hospital of Philadelphia, outlined results of the multicenter MILES trial, which indicated that Viaskin Milk Epicutaneous Immunotherapy was well tolerated by patients aged two to 17 years with an IgE-mediated cow’s milk protein allergy.
In phase 1 of the MILES study, 18 children aged 2-17 were enrolled to explore the safety of three different doses of Viaskin Milk (150 micrograms, 300 micrograms or 500 micrograms) when compared to placebo in a 2:1 ratio following a 3-week course of treatment.
“Almost identical to what was seen with the peanut patch, [this study showed] there were really no safety concerns,” Spergel told Healio.com/Allergy. “They have not talked about efficacy yet, but we know it is safe. The phase 2 study, which will determine efficacy and dose ranging, is now ongoing and currently recruiting.”